Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [02/19/2020 10:29 PST] Fennec Pharmaceuticals Inc. (NASDAQ:FENC), Up By 100.00% ($7.19) From $7.190 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/14/2020 11:07 PST] Fennec Pharmaceuticals Inc. (NASDAQ:FENC), Up By 100.00% ($6.66) From $6.660 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/13/2020 07:46 PST] FENC Expected to Trade Up After Bullish Patterns Develop
• [02/11/2020 11:45 PST] Fennec Pharmaceuticals Inc. (NASDAQ:FENC), Up By 100.00% ($6.59) From $6.590 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/05/2020 07:40 PST] FENC Expected to Trade Up After Bullish Patterns Develop
• [02/03/2020 07:26 PST] FENC Expected to Trade Up After Bullish Patterns Develop
• [01/17/2020 07:42 PST] FENC Expected to Trade Down After Bearish Patterns Develop
• [01/13/2020 10:10 PST] Fennec Pharmaceuticals Inc. (NASDAQ:FENC), Up By 100.00% ($6.08) After BUYINS.NET SqueezeTrigger Report Released on Monday, December 23rd 2019 at a Price of $6.080.
• [12/23/2019 08:16 PST] FENC SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.